» Articles » PMID: 32568632

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

Abstract

Purpose: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS).

Patients And Methods: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size.

Results: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort.

Conclusion: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.

Citing Articles

Experiences and preferences about information on treatment-related side effects among patients with early breast cancer.

Di Meglio A, Catanuto G, Zambon M, Chan A, Kassianos A, Cloconi C Breast. 2025; 80:104414.

PMID: 39947086 PMC: 11872395. DOI: 10.1016/j.breast.2025.104414.


Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.

Krukowski R, Hu X, Arshad S, Anderson J, Stepanski E, Vidal G JCO Clin Cancer Inform. 2024; 8:e2400179.

PMID: 39642329 PMC: 11631045. DOI: 10.1200/CCI-24-00179.


Is tamoxifen good enough for the Asian population in ER+ HER2- post-menopausal women with early breast cancer? A nationwide population-based cohort study.

Chang C, Lee Y, Huang C, Lu Y PLoS One. 2024; 19(11):e0313120.

PMID: 39602456 PMC: 11602078. DOI: 10.1371/journal.pone.0313120.


Menopausal Hormone Therapy in Breast Cancer Survivors.

Culhane R, Zaborowski A, Hill A Cancers (Basel). 2024; 16(19).

PMID: 39409888 PMC: 11475154. DOI: 10.3390/cancers16193267.


Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial.

Henry N, Unger J, Vaidya R, Darke A, Skaar T, Fisch M Contemp Clin Trials. 2024; 147:107712.

PMID: 39395534 PMC: 11620912. DOI: 10.1016/j.cct.2024.107712.


References
1.
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt S . Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011; 89(5):718-25. PMC: 3081375. DOI: 10.1038/clpt.2011.32. View

2.
McCowan C, Wang S, Thompson A, Makubate B, Petrie D . The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013; 109(5):1172-80. PMC: 3778308. DOI: 10.1038/bjc.2013.464. View

3.
Abrahams H, Gielissen M, Schmits I, Verhagen C, Rovers M, Knoop H . Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016; 27(6):965-974. DOI: 10.1093/annonc/mdw099. View

4.
Barron T, Cahir C, Sharp L, Bennett K . A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer. 2013; 109(6):1513-21. PMC: 3777010. DOI: 10.1038/bjc.2013.518. View

5.
Austin P . The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2013; 33(7):1242-58. PMC: 4285179. DOI: 10.1002/sim.5984. View